Pelican Cancer Foundation

Pelican Cancer Foundation

  • Facebook
  • Instagram
  • Twitter
  • YouTube
DONATE NOW
  • Home
  • About Us
    • What we do
      • Bowel cancer
      • Colorectal Liver Metastases
      • Prostate cancer
      • Bladder cancer
      • Pseudomyxoma peritonei
      • Our Research
      • Our achievements
      • Media
    • Who we are
      • Our board
      • Our team
      • Pelican Patrons
    • Our annual accounts
    • Pelican Cancer Foundation – What next?
    • Support Us
    • Job opportunities
    • Partners
  • Workshops
    • TIPTOP
      • Workshops
      • TIPTOP – Online resources
    • Pelican IMPACT
      • IMPACT – Completion & Evaluation
      • Workshops
      • IMPACT – Online resources
      • IMPACT – Partners and Sponsors
    • SPECC
      • SPECC – Completion & Evaluation
      • Workshops
      • SPECC – Online resources
      • SPECC – Partners and Sponsors
    • LOREC
    • What clinicians say about our courses
    • Faculty
    • Our sponsors
    • Become a sponsor
    • Request a course or topic
    • Give us feedback
    • Previous courses
  • Research
    • Research strategy
    • Bowel cancer research
      • POLARS
      • MERCURY 2 (Low Rectal Cancer Study)
      • Deferral of surgery study
      • TATME
      • IMPRESS
      • TRIGGER
      • Papers of interest
      • Timing of surgery
      • AMSOEC
      • MINSTREL
      • Completed research
        • Perineal wound healing registry
        • Beyond TME
        • Validation of the LARS score
        • MARVEL: Evaluation of EMVI positive rectal cancer
        • FLEX
        • TME Physical Simulation Model
        • Total Mesorectal Excision (TME)
        • MERCURY research programme
    • Peritoneal malignancy research
      • Colorectal Peritoneal Malignancy Database
      • Pseudomyxoma Pathology Atlas
    • Prostate Cancer Research
      • Focal therapy and HIFU research
      • MRI research for prostate cancer
      • Prostate cancer colloquiums
      • FORECAST
      • Trachtomap
      • Papers of interest
    • Liver cancer research
      • Completed research
        • EORTC studies
      • SERENADE
      • Papers of interest
    • Bladder cancer research
      • PELT
      • Papers of interest
    • Peer reviewers
    • Clinical trials
    • Information for researchers
      • Peer review process
      • Research review panel
      • Research Grant Application Guidance Notes
      • Terms and conditions of grants
      • Animals in medical research
      • Research costs
    • Surgical videos
  • For Patients
    • Patient stories
      • Bob’s story (prostate cancer)
      • Andrew’s story (prostate cancer)
      • Alan’s story (prostate cancer)
      • Raymond’s story (prostate cancer)
      • Anthony’s story (bowel cancer)
      • Elena’s story (bowel cancer)
      • Jay’s story (bladder cancer)
      • Terry’s story (liver cancer)
      • Derrick’s story (liver cancer)
      • Alex’s story (colorectal cancer)
      • Cheryll’s story (rectal cancer)
      • Eileen’s story
      • Richard’s story – irrigation
      • Tom’s story – complete response
      • Advanced metastatic bowel cancer
    • Bowel cancer
      • Our bowel cancer team
      • About bowel cancer treatment – TME
      • Low rectal cancer
      • Complete response to chemoradiotherapy in rectal cancer
      • Frequently asked questions about bowel cancer
      • Irrigation for colostomies
      • A patient’s advice
      • Symptom checker
      • Bowel cancer – useful contacts
    • Liver cancer
      • Our liver cancer team
      • About liver cancer treatment
      • Interventional radiology
      • Liver cancer – frequently asked questions
      • Carcinoid and neuroendocrine tumours
      • Liver cancer – want to read more?
    • Prostate cancer
      • Our prostate cancer team
      • Prostate cancer treatment options
      • Pelican’s position
    • Bladder cancer
      • Blue light cystoscopy
      • Bladder cancer – useful contacts
    • Pseudomyxoma peritonei
    • Kidney cancer
      • Our kidney cancer team
      • Kidney cancer – useful contacts
    • What is an MDT?
      • What an MRI reveals
      • Reporting cancer outcomes
    • Getting a second opinion
    • Clinical trials
      • Current clinical trials
    • Tell us your story
    • Still got questions about cancer?
    • Links
  • Support us
    • Make a donation
      • Make a donation
      • Why donate to Pelican?
      • Donate shares
      • Donate in memory
      • How your donations are spent
    • Fundraising
      • Our fundraisers
      • Fundraising ideas
      • Fundraising challenges
      • Fundraising resources
      • Our events
    • Leaving a Legacy
    • Volunteering Opportunities
    • Could you host a Pelican Talk?
    • Charity of the Year partnerships
    • Pelican Film Society
  • Online Shop
  • Events
  • Contact us

Complete response to chemoradiotherapy in rectal cancer

Pelican hosted two expert meetings to discuss Watch and Wait for rectal cancer in 2017. At both meetings there were presentations on the information and consent that patients entered into Watch and Wait may ask. These questions and answers below are based on one of these talks.

• Am I missing an opportunity for a better result if I defer surgery in the hope of sustained cCR?
The majority of patients entered into a Watch and Wait protocol with a cCR were originally expected to have surgery. Patients may enter a Watch and Wait protocol if their tumour has regressed (shrunk). If the tumour does not regrow, there may be the opportunity to avoid surgery, preserve the rectum and retain better bowel function. Whilst clinicians at the Pelican meetings were positive about deferring surgery, the research evidence is controversial; studies are mostly retrospective cohort studies and there remains uncertainty amongst some clinicians about this treatment option.

• Am I more likely to suffer metastatic disease if I adopt Watch and Wait, rather than excision?
Patients with Stage II or III rectal cancer have up to a 35% risk of developing metastases 13. In the studies presented at the meetings, the metastatic rate for patients with a cCR varied, with an average metastatic rate of approximately 8% (unpublished data).

• Do a reasonable number of colorectal surgeons in the UK agree with Watch and Wait?
These two meetings brought together more than 100 clinicians and presented data from the Christie Hospital in Manchester, which included data from four hospitals in the UK who followed up patients with a cCR. In 2007 and 2013, questionnaires were sent out to surgeons in England, 122 and 138 surgeons replied and there was a shift in the six year period, with the more recent survey reporting that 64% said they would discuss Watch and Wait management for rectal cancer with their patients14, 15.

• Does cCR equate to my nodes being clear?
Absolute certainty that the nodes are clear can only be achieved by pathological assessment, which requires an operation. However, radiological imaging features can be used to diagnose and monitor suspicious nodes.

• If I get regrowth post-CRT, what is my chance of cure, compared with a recurrence after surgery?
This is a different concept to recurrence after surgery since no tumour has been removed, and is therefore referred to as a regrowth. The majority of patients who have a regrowth can have salvage surgery12. This has been shown by centres in Brazil, Holland, USA, Denmark and UK with patients having good outcomes in terms of disease-free survival.

• What is the chance of a local relapse with Watch and Wait?
Between 20 to 38% of patients who have a cCR and join a Watch and Wait protocol have a regrowth compared to <10% recurrence after surgery. However the prognosis is completely different between the two as a regrowth can still have successful salvage surgery.

• Am I trading life expectancy to avoid a permanent stoma? How much life expectancy?
There does not appear to be a trade-off in life expectancy and, in fact, good or complete response is a marker of good prognosis.

• Do many patients in the UK accept the risk of Watch and Wait?
This is increasingly common. In the published literature, 129 patients from north-west England5 and 6 patients from Exeter16 have avoided surgery and been followed up with a Watch and Wait protocol. But many more patients with a cCR from individual centres are avoiding surgery.

• Will the follow-up needed for Watch and Wait be different from that after post-CRT resection? In what way?
Follow-up after surgery varies, but will mostly include an annual CT scan, blood tests and full colonoscopy in varying frequency. Most centres will discharge patients after 5 years if that patient is disease free. In Watch and Wait, more frequent follow-ups are recommended and includes MRI scan with more frequent endoscopy.

• Am I more likely to need secondary chemotherapy after Watch and Wait, compared with timely resection?
There is no evidence that adjuvant chemotherapy has any benefit in patients managed under a Watch and Wait programme. Some centres will give additional chemotherapy to some patients, but this is not standardised.

• If I do not respond to CRT, would you recognise my non-response?
Patients who do not have a cCR will go on to have surgery.

• If not, would I be disadvantaged by delaying definitive surgery?
The published data and results of these two meetings suggest that patients are not disadvantaged by delaying surgery in patients with cCR.

13. Breugom AJ, Swets M, Bosset J-F, Collette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. The Lancet Oncology. 2015;16(2):200-7.
14. Wynn GR, Bhasin N, Macklin CP, George ML. Complete clinical response to neoadjuvant chemoradiotherapy in patients with rectal cancer: opinions of British and Irish specialists. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2010;12(4):327-33.
15. Sao Juliao GP, Smith FM, Macklin CP, George ML, Wynn GR. Opinions have changed on the management of rectal cancer with a complete clinical response to neoadjuvant chemoradiotherapy. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2014;16(5):392-4.
16. Dalton RSJ, Velineni R, Osborne ME, Thomas R, Harries S, Gee AS, et al. A single-centre experience of chemoradiotherapy for rectal cancer: is there potential for nonoperative management? Colorectal Disease. 2012;14(5):567-71.

Pelican Cancer FoundationFollow

Pelican Cancer Foundation
Pelican_CancerPelican Cancer Foundation@Pelican_Cancer·
5h

#BowelCancerAwarenessMonth #PelicanCancerFoundation

Reply on Twitter 1382936796049272833Retweet on Twitter 13829367960492728331Like on Twitter 13829367960492728331Twitter 1382936796049272833
Pelican_CancerPelican Cancer Foundation@Pelican_Cancer·
15 Apr

#BowelCancerAwarenessMonth #PelicanCancerFoundation

Reply on Twitter 1382574408661864450Retweet on Twitter 13825744086618644503Like on Twitter 13825744086618644502Twitter 1382574408661864450
Pelican_CancerPelican Cancer Foundation@Pelican_Cancer·
14 Apr

#BowelCancerAwarenessMonth #PelicanCancerFoundation

Reply on Twitter 1382212019726680067Retweet on Twitter 13822120197266800671Like on Twitter 13822120197266800671Twitter 1382212019726680067
Load More...

To view our privacy policy - click here.
Registered charity no: 1141911

Copyright © 2021 · Outreach Pro Theme on Genesis Framework · WordPress · Log in